首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
考研
Obesity is an epidemic to some and an opportunity to others. More than two-thirds of Americans are overweight. Find a way to bat
Obesity is an epidemic to some and an opportunity to others. More than two-thirds of Americans are overweight. Find a way to bat
admin
2019-06-03
58
问题
Obesity is an epidemic to some and an opportunity to others. More than two-thirds of Americans are overweight. Find a way to battle obesity, 【C1】______a huge profit might be made. On February 22nd, 2013 one pharmaceutical firm, Vivus, took a small【C2】______towards this goal. A committee advising America’ s Food and Drug Administration(FDA)recommended Vivus’ s diet drug, Qnexa.【C3】______, the pill’ s long-awaited final approval may not come until April. The announcement mostly served as a reminder of a struggle which【C4】______fat into gold.
Medical-device and pharmaceutical companies are quite【C5】______treating the problems that come with obesity. However, they can’t help consumers【C6】______weight. Allergan, a device-maker, has tried to use its gastric bands to enter the obesity market. The band is fitted near the top of patients’ stomach, which helps them feel full【C7】______during the meal. Allergan has captured about 70% of the worldwide market for gastric bands, but sales are now【C8】______. The recession has sapped consumers’ desire for expensive surgery. Some patients have【C9】______bands removed because they slipped or proved【C10】______. In January David Pyott, Allergan’s chief executive, said he would cancel an effort to market the band for teenagers. He is now trying to convince insurers of the gastric band’ s【C11】______.
Drug companies have had even more【C12】______than device-makers. It has been 13 years since the FDA approved a【C13】______diet pill. That drug, Roche’s Xenical, has【C14】______side-effects. The FDA rejected Vivus’s Qnexa in 2010 over【C15】______for the safety of pregnant women and the quickening of patients’ heart rates.
However, Vivus’ s new data in 2013 apparently satisfied the FDA’ s advisory committee.
But the agency may yet【C16】______the drug.【C17】______Qnexa is approved, it is unclear that patients will buy it. Qnexa【C18】______two medicines that are already on the market. Both medicines are generic, which means that doctors may【C19】______the existing drugs rather than Qnexa’s more expensive version. For now, it is more【C20】______to treat fat patients than to try to make them slim.
【C20】
选项
A、important
B、quick
C、profitable
D、helpful
答案
C
解析
本题考查形容词辨析。根据文章首句“肥胖症对某些人来说是传染病,对别的一些人来说则是机遇”和第二段前两句“医疗器械公司和制药公司非常善于解决肥胖带来的问题,但是它们无法帮助消费者减轻体重”可知,医疗器械公司和制药公司利用这一机遇,通过治疗肥胖患者来获利。故C.profitable“有利可图的,可赚钱的”为正确答案。important“重要的”,quick“迅速的”,helpful“有益的,给予帮助的”,均不符合文意,故排除。
转载请注明原文地址:https://kaotiyun.com/show/PxnZ777K
0
考研英语一
相关试题推荐
Directions:Inthispart,youareaskedtowriteanessaybasedonthefollowingchart.Inyourwriting,youshould1)inte
ThepeoplewhorunFacebookarefuriousaboutanewmoviethatdepictstheexistenceofFace-book.They’reupsetbecausemuchof
Themethodsoftestingaperson’sknowledgeandabilityremainasprimitiveasevertheywere.Afteralltheseyears,education
Americanstodaydon’tplaceaveryhighvalueonintellect.Ourheroesareathletes,entertainers,andentrepreneurs,notschol
InhisbookTheTippingPoint,MalcolmGladwellarguesthat"socialepidemics"aredriveninlargepartbytheactionsofatiny
InhisbookTheTippingPoint,MalcolmGladwellarguesthat"socialepidemics"aredriveninlargepartbytheactionsofatiny
Intheearly1960sWiltChamberlainwasoneofonlythreeplayersintheNationalBasketballAssociation(NBA)listedatoverseve
Therearetwobasicwaystoseegrowth:oneasaproduct,theotherasaprocess.Peoplehavegenerallyviewedpersonalgrowtha
随机试题
试述我国公务员职位类别的标准与类别的划分。
品牌扩展策略
属于甲类传染病的是
急性淋病的首选治疗药物是( )
该项目环评的主要因素应包括哪些内容?对水环境进行环境风险评价时,评价因子应包括哪些?大气环境影响预测与评价的评价因子包括哪些?
下列不属于劳动争议的是()。
采取委托银行收款方式销售货物,增值税纳税义务发生时间为收取销售款的当天。()
红细胞转酮醇酶活性可反映机体()的营养状况。
【F1】Environmentalistsandactivistsaccusedtheworld’srichnationsofmanagingaglobalconferenceongeneticallymodifiedfoo
Coastalenvironmentalprotectionisan【C1】______partoftheTexasGeneralLandOfficemission.Theagency【C2】_______coastal
最新回复
(
0
)